Table 5.
Correlation analysis of candidate gene methylation levels with methamphetamine abuse characteristics in three groups (r).
HMAQ group (n = 168) | LMAQ group (n = 39) | Health control (n = 105) | |||||
---|---|---|---|---|---|---|---|
Age | Age of first drug abuse | Total drug abuse time (months) | Age | Age of first drug abuse | Total drug abuse time (months) | Age | |
CAV2 | −0.101 | 0.105 | −0.069 | 0.351* | 0.308 | 0.405* | 0.078 |
BHLHB9 | 0.103 | 0.129 | 0.145 | 0.288 | 0.368* | 0.312* | −0.132 |
PCSK9 | −0.014 | 0.004 | 0.156 | −0.235 | −0.191 | 0.134 | 0.046 |
SLC1A6 | 0.146 | −0.098 | 0.009 | 0.117 | 0.129 | −0.059 | 0.017 |
LYNX1 | 0.023 | −0.044 | 0.104 | −0.149 | −0.057 | −0.203 | −0.129 |
Methylation copies of the CAV2 gene were significantly associated with age and total duration of drug abuse in the LMAQ group. The methylated copies of the BHLHB9 gene were significantly correlated with the age of first drug abuse and the total duration of drug abuse in the LMAQ group.
p < 0.05.